Supriya Lifescience Limited
NSE: SUPRIYA BSE: SUPRIYA
Prev Close
580.85
Open Price
590
Volume
105,837
Today Low / High
585.8 / 606.95
52 WK Low / High
573.4 / 842
Range
575 - 635
Prev Close
581
Open Price
584.7
Volume
5,703
Today Low / High
584.7 / 607.45
52 WK Low / High
573.45 / 841.7
Range
575 - 635
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 604.8 (target range: 575 - 635), reflecting a change of 23.95 (4.12327%). On the BSE, it is listed at 604.75 (target range: 575 - 635), showing a change of 23.75 (4.08778%). Both the NSE and BSE data indicate positive movement, suggesting the stock is on an upward trend. This could be an attractive opportunity for investors looking for growth.
Supriya Lifescience Limited Graph
Supriya Lifescience Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Supriya Lifescience Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 604.80, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 604.75 | 610.80 | 549.72 - 671.88 |
| 616.85 | 493.48 - 740.21 | ||
| 622.89 | 436.02 - 809.76 | ||
| Bearish Scenario | 604.75 | 598.70 | 538.83 - 658.57 |
| 592.66 | 474.12 - 711.19 | ||
| 586.61 | 410.63 - 762.59 |
Overview of Supriya Lifescience Limited
ISIN
INE07RO01027
Industry
Biotechnology
Vol.Avg
135,839
Market Cap
51,154,867,680
Last Dividend
1
Official Website
IPO Date
2021-12-28
DCF Diff
857.64
DCF
-222
Financial Ratios Every Investor Needs
Stock Dividend of SUPRIYA
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2025-09-04 | September 04, 25 | 1 | 1 | 2025-09-05 | 2025-10-24 | |
| 2024-09-20 | September 20, 24 | 0.8 | 0.8 | 2024-09-20 | 2024-10-27 | |
| 2023-09-15 | September 15, 23 | 0.6 | 0.6 | 2023-09-15 | 2023-10-29 | |
| 2022-09-01 | September 01, 22 | 0.6 | 0.6 | 2022-09-02 | 2022-10-16 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 696.49 Cr | 312.14 Cr | 384.35 Cr | 0.5518 | 0.00 Cr | 80.52 Cr | 240.35 Cr | 187.96 Cr | 23.35 | 270.61 Cr | 0.2699 |
| 2024-03-31 | 570.34 Cr | 360.86 Cr | 280.25 Cr | 0.4914 | 6.69 Cr | 23.19 Cr | 157.17 Cr | 119.11 Cr | 14.80 | 183.58 Cr | 0.2088 |
| 2023-03-31 | 451.02 Cr | 180.81 Cr | 280.13 Cr | 0.6211 | 5.40 Cr | 19.23 Cr | 115.32 Cr | 89.86 Cr | 11.16 | 136.98 Cr | 0.1992 |
| 2022-03-31 | 519.37 Cr | 229.89 Cr | 289.49 Cr | 0.5574 | 1.66 Cr | 13.73 Cr | 202.16 Cr | 151.81 Cr | 18.86 | 221.56 Cr | 0.2923 |
| 2021-03-31 | 385.37 Cr | 151.17 Cr | 234.20 Cr | 0.6077 | 0.66 Cr | 10.52 Cr | 164.44 Cr | 123.59 Cr | 16.89 | 176.99 Cr | 0.3207 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 76.06 Cr | 1,112.31 Cr | 115.56 Cr | 996.7600 Cr | 5.38 Cr | -73.77 Cr | 118.35 Cr | 599.49 Cr | 0.00 Cr | 0.00 Cr | 63.24 Cr | 82.1620 Cr |
| 2024-03-31 | 68.17 Cr | 921.24 Cr | 105.87 Cr | 815.3660 Cr | 5.49 Cr | -62.68 Cr | 85.25 Cr | 457.30 Cr | 14.87 Cr | 0.00 Cr | 63.80 Cr | 76.8940 Cr |
| 2023-03-31 | 85.25 Cr | 820.28 Cr | 120.82 Cr | 699.4590 Cr | 22.47 Cr | -62.78 Cr | 115.77 Cr | 328.06 Cr | 1.66 Cr | 0.00 Cr | 25.30 Cr | 95.7800 Cr |
| 2022-03-31 | 165.78 Cr | 734.76 Cr | 119.08 Cr | 615.6880 Cr | 27.42 Cr | -138.36 Cr | 92.31 Cr | 231.67 Cr | 25.45 Cr | 2.93 Cr | 0.05 Cr | 99.6990 Cr |
| 2021-03-31 | 31.07 Cr | 445.82 Cr | 176.88 Cr | 268.9420 Cr | 72.19 Cr | 41.12 Cr | 72.48 Cr | 175.92 Cr | 17.60 Cr | 20.79 Cr | 0.05 Cr | 146.0190 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 172.5650 Cr | -161.8200 Cr | -6.5470 Cr | 10.1890 Cr | 4.1980 Cr | 79.1540 Cr | -162.3760 Cr | 187.9580 Cr | -0.1080 Cr | -6.4390 Cr | -33.1000 Cr |
| 2024-03-31 | 113.3070 Cr | -173.5750 Cr | -22.3590 Cr | -32.3480 Cr | -82.6260 Cr | 74.9560 Cr | -145.6550 Cr | 119.1140 Cr | -16.6250 Cr | -4.8290 Cr | 30.5210 Cr |
| 2023-03-31 | 66.1870 Cr | -133.1450 Cr | -9.7770 Cr | -42.2130 Cr | -70.3260 Cr | 157.5820 Cr | -108.4000 Cr | 123.4870 Cr | -4.6700 Cr | -4.8290 Cr | -23.4580 Cr |
| 2022-03-31 | 48.8010 Cr | -59.8220 Cr | 149.6520 Cr | -11.1030 Cr | 138.6310 Cr | 227.9080 Cr | -59.9040 Cr | 207.2450 Cr | -0.7630 Cr | -4.3910 Cr | -19.8320 Cr |
| 2021-03-31 | 75.8890 Cr | -46.8010 Cr | -14.5160 Cr | 31.6890 Cr | 14.5720 Cr | 92.2930 Cr | -48.2410 Cr | 167.3930 Cr | -11.6660 Cr | -3.9560 Cr | -23.0220 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | 206.44 Cr | 61.20 Cr | 145.24 Cr | 0.7035 | 65.26 Cr | 49.68 Cr | 6.17 | 74.24 Cr | 0.2406 |
| 2025-09-30 | 199.83 Cr | 55.73 Cr | 144.10 Cr | 0.7211 | 66.01 Cr | 50.43 Cr | 6.27 | 75.37 Cr | 0.2523 |
| 2025-06-30 | 145.07 Cr | 31.77 Cr | 113.30 Cr | 0.7810 | 45.25 Cr | 34.79 Cr | 4.32 | 54.38 Cr | 0.2398 |
| 2025-03-31 | 184.11 Cr | 81.88 Cr | 102.23 Cr | 0.5552 | 61.50 Cr | 50.38 Cr | 6.26 | 70.56 Cr | 0.2737 |
| 2024-12-31 | 185.65 Cr | 61.78 Cr | 123.87 Cr | 0.6672 | 60.99 Cr | 46.78 Cr | 5.82 | 68.05 Cr | 0.2520 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 99.26 Cr | 6.98 Cr | 106.24 Cr | 155.94 Cr | 142.81 Cr | 505.05 Cr | 628.80 Cr | 1,202.96 Cr | 121.16 Cr |
| 2025-06-30 | 0.00 Cr | 0.00 Cr | 79.15 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -996.76 Cr |
| 2025-03-31 | 79.15 Cr | 0.00 Cr | 79.15 Cr | 134.36 Cr | 118.35 Cr | 437.04 Cr | 599.49 Cr | 1,112.31 Cr | 115.56 Cr |
| 2024-12-31 | 0.00 Cr | 0.00 Cr | 84.31 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -905.89 Cr |
| 2024-09-30 | 77.51 Cr | 9.46 Cr | 86.96 Cr | 105.73 Cr | 107.99 Cr | 413.36 Cr | 522.68 Cr | 1,012.39 Cr | 106.50 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | 34.79 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2025-03-31 | 50.38 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-12-31 | 46.78 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-09-30 | 46.15 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-06-30 | 44.64 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| No split history data available. | ||
Similar Stocks: Biotechnology
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Biocon Limited | BIOCON | ₹395.80 | ₹502,336,973,043.00 | ₹3,554,697.00 |
| Anthem Biosciences Ltd. | ANTHEM | ₹670.15 | ₹376,432,537,248.00 | ₹141,357.00 |
| Piramal Pharma Limited | PPLPHARMA | ₹155.37 | ₹205,611,590,763.00 | ₹1,450,331.00 |
| Onesource Specialty Pharma Ltd. | ONESOURCE | ₹1,473.90 | ₹168,940,186,680.00 | ₹277,137.00 |
| Syngene International Limited | SYNGENE | ₹409.30 | ₹164,437,005,191.00 | ₹675,182.00 |
| Concord Biotech Limited | CONCORDBIO | ₹1,197.20 | ₹125,246,519,429.00 | ₹100,555.00 |
| Jubilant Ingrevia Limited | JUBLINGREA | ₹570.75 | ₹90,184,712,614.00 | ₹363,355.00 |
| Blue Jet Healthcare Limited | BLUEJET | ₹376.10 | ₹65,240,346,343.00 | ₹357,325.00 |
| Supriya Lifescience Limited | SUPRIYA | ₹604.80 | ₹48,675,997,440.00 | ₹105,837.00 |
| Zota Health Care Limited | ZOTA | ₹1,176.70 | ₹35,692,435,139.00 | ₹47,409.00 |
| Dishman Carbogen Amcis Limited | DCAL | ₹164.51 | ₹25,792,386,958.00 | ₹431,232.00 |
Key Executives
Gender: female
Year Born: 1990
Gender: male
Year Born: 1964
Gender: female
Year Born: 1958
Gender: male
Year Born:
Gender: female
Year Born:
Gender: female
Year Born: 1991
Gender: Not Specified
Year Born: 1955
Gender: Not Specified
Year Born:
Gender: Not Specified
Year Born:
Gender: Not Specified
Year Born:
FAQs about Supriya Lifescience Limited
The CEO is Satish Waman Wagh.
The current price is ₹635.60.
The range is ₹567.05-842.
The market capitalization is ₹5,115.49 crores.
The dividend yield is 0.16%.
The P/E ratio is 27.62.
The company operates in the Healthcare sector.
Overview of Supriya Lifescience Limited (ISIN: INE07RO01027) is a leading Biotechnology in India. With a market capitalization of ₹5,115.49 crores and an average daily volume of 135,839 shares, it operates in the Biotechnology. The company last declared a dividend of ₹1.